A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni Bezzi C, Scalese M, Dozza L, Marzocchi G, Martello M, Barilà G, Antonioli E, Staderini M, Buda G, Petrini M, Cea M, Quaresima M, Furlan A, Bonalumi A, Cavo M, Zamagni E.
Rocchi S, et al. Among authors: scalese m.
Hematol Oncol. 2021 Feb;39(1):41-50. doi: 10.1002/hon.2820. Epub 2020 Nov 1.
Hematol Oncol. 2021.
PMID: 33085797
Clinical Trial.